Cost-Effectiveness of Sleeve Gastrectomy and Gastric Bypass As Revisional Surgery on Antidiabetic Reimbursement: A Nationwide Cohort Study

Overview

Journal Ann Surg Open

Publisher Wolters Kluwer

Specialty General Surgery

Date 2024 Jun 24

PMID 38911633

Authors

Jeremie Thereaux

Mohammed Bennani

Jean Khemis

Elisabeth Ohayon

Isabelle Visnovec Buissez

Alexandre Lafourcade

Laetitia Quiriconi

Caroline Philippe

Jean-Michel Oppert

Affiliations

Soon will be listed here.

Abstract

Objective: This study compared the effectiveness of 4 main revisional bariatric surgery (RBS) sequences after sleeve gastrectomy (SG) and adjustable gastric banding (AGB), on the reimbursement of antidiabetic treatments in France.

Background: Few large-scale prospective cohort studies have assessed the changes in antidiabetic treatments after RBS.

Method: This nationwide observational population-based cohort study analyzed data from the French National Health Insurance Database. All patients who underwent primary SG and AGB in France between January 2012 and December 2014 were included and followed up until December 31, 2020. The changes in categories and costs of reimbursed antidiabetic treatments across different RBS sequences were assessed (presented as follows: bariatric surgery (BS)-RBS).

Results: Among the 107,088 patients who underwent BS, 6396 underwent RBS, 2400 SG-GBP (SG converted to gastric bypass [GBP] during follow-up), 2277 AGB-SG, 1173 AGB-GBP, and 546 SG-SG. Pre-RBS insulin was used in 10 (2.9%), 4 (0.9%), 8 (2.4%), and 10 (2.6%) patients, respectively. Two years after RBS, the treatment discontinuation or decrease (the change of treatment to a lighter one category rates [eg, insulin to bi/tritherapy]) was 47%, 47%, 49%, and 34%, respectively. Four years after RBS, the median annual cost per patient compared with baseline was lower ( < 0.01) for all sequences, except SG-SG ( = 0.24). The most notable effect concerned AGB-GBP (median of more than 220 euros to 0).

Conclusions: This study demonstrated the positive impact of RBS over a 4-year follow-up period on antidiabetic treatments reimbursement, through the reduction or discontinuation of treatments and a significant decrease in costs per patient.

References

Kim D, Arterburn D, Sullivan S, Basu A . Economic Value of Greater Access to Bariatric Procedures for Patients With Severe Obesity and Diabetes. Med Care. 2018; 56(7):583-588. DOI: 10.1097/MLR.0000000000000924. View

Thereaux J, Veyrie N, Barsamian C, Corigliano N, Beauchet A, Poitou C . Similar postoperative safety between primary and revisional gastric bypass for failed gastric banding. JAMA Surg. 2014; 149(8):780-6. DOI: 10.1001/jamasurg.2014.625. View

Lazzati A . Epidemiology of the surgical management of obesity. J Visc Surg. 2023; 160(2S):S3-S6. DOI: 10.1016/j.jviscsurg.2022.12.004. View

Thereaux J, Lesuffleur T, Czernichow S, Basdevant A, Msika S, Nocca D . Association Between Bariatric Surgery and Rates of Continuation, Discontinuation, or Initiation of Antidiabetes Treatment 6 Years Later. JAMA Surg. 2018; 153(6):526-533. PMC: 5875344. DOI: 10.1001/jamasurg.2017.6163. View

Thereaux J, Lesuffleur T, Czernichow S, Basdevant A, Msika S, Nocca D . Multicentre cohort study of antihypertensive and lipid-lowering therapy cessation after bariatric surgery. Br J Surg. 2018; 106(3):286-295. DOI: 10.1002/bjs.10999. View

Uittenbogaart M, Leclercq W, Luijten A, van Dielen F . Laparoscopic Adjustable Gastric Banding After Failed Roux-En-Y Gastric Bypass. Obes Surg. 2016; 27(2):381-386. DOI: 10.1007/s11695-016-2283-0. View

Lazzati A, Antonio M, Paolino L, Martini F, Azoulay D, Iannelli A . Natural History of Adjustable Gastric Banding: Lifespan and Revisional Rate: A Nationwide Study on Administrative Data on 53,000 Patients. Ann Surg. 2016; 265(3):439-445. DOI: 10.1097/SLA.0000000000001879. View

Thereaux J, Lesuffleur T, Czernichow S, Basdevant A, Msika S, Nocca D . Long-term adverse events after sleeve gastrectomy or gastric bypass: a 7-year nationwide, observational, population-based, cohort study. Lancet Diabetes Endocrinol. 2019; 7(10):786-795. DOI: 10.1016/S2213-8587(19)30191-3. View

Wolnerhanssen B, Peterli R, Hurme S, Bueter M, Helmio M, Juuti A . Laparoscopic Roux-en-Y gastric bypass versus laparoscopic sleeve gastrectomy: 5-year outcomes of merged data from two randomized clinical trials (SLEEVEPASS and SM-BOSS). Br J Surg. 2021; 108(1):49-57. DOI: 10.1093/bjs/znaa011. View

10.

Sakran N, Soued S, Hod K, Buchwald J, Soifer K, Kessler Y . Long-Term Matched Comparison of Primary and Revisional Laparoscopic Sleeve Gastrectomy. Obes Surg. 2023; 33(3):695-705. PMC: 9809525. DOI: 10.1007/s11695-022-06436-8. View

11.

Thereaux J, Lesuffleur T, Czernichow S, Basdevant A, Msika S, Nocca D . To What Extent Does Posthospital Discharge Chemoprophylaxis Prevent Venous Thromboembolism After Bariatric Surgery?: Results From a Nationwide Cohort of More Than 110,000 Patients. Ann Surg. 2017; 267(4):727-733. DOI: 10.1097/SLA.0000000000002285. View

12.

Labul M, Wysocki M, Bartosiak K, Orlowski M, Katkowski B, Jaworski P . Analysis of the Factors Contributing to Bariatric Success After Laparoscopic Redo Bariatric Procedures: Results from Multicenter Polish Revision Obesity Surgery Study (PROSS). Obes Surg. 2022; 32(12):3879-3890. PMC: 9672013. DOI: 10.1007/s11695-022-06306-3. View

13.

Dang J, Vaughan T, Mocanu V, Mubashir H, Barajas-Gamboa J, Codina R . Conversion of Sleeve Gastrectomy to Roux-en-Y Gastric Bypass: Indications, Prevalence, and Safety. Obes Surg. 2023; 33(5):1486-1493. PMC: 10017068. DOI: 10.1007/s11695-023-06546-x. View

14.

Carlsson L, Sjoholm K, Jacobson P, Andersson-Assarsson J, Svensson P, Taube M . Life Expectancy after Bariatric Surgery in the Swedish Obese Subjects Study. N Engl J Med. 2020; 383(16):1535-1543. PMC: 7580786. DOI: 10.1056/NEJMoa2002449. View

15.

Gero D, Vannijvel M, Okkema S, Deleus E, Lloyd A, Lo Menzo E . Defining Global Benchmarks in Elective Secondary Bariatric Surgery Comprising Conversional, Revisional, and Reversal Procedures. Ann Surg. 2021; 274(5):821-828. DOI: 10.1097/SLA.0000000000005117. View

16.

Schauer P, Bhatt D, Kirwan J, Wolski K, Aminian A, Brethauer S . Bariatric Surgery versus Intensive Medical Therapy for Diabetes - 5-Year Outcomes. N Engl J Med. 2017; 376(7):641-651. PMC: 5451258. DOI: 10.1056/NEJMoa1600869. View

17.

Ngomba Muakana J, Thissen J, Loumaye A, Thoma M, Deswysen Y, Navez B . Distalization of Standard Roux-en-Y Gastric Bypass: Indications, Technique, and Long-Term Results. Obes Surg. 2023; 33(5):1373-1381. DOI: 10.1007/s11695-023-06524-3. View

18.

Lauren B, Lim F, Krikhely A, Taveras E, Woo Baidal J, Bellows B . Estimated Cost-effectiveness of Medical Therapy, Sleeve Gastrectomy, and Gastric Bypass in Patients With Severe Obesity and Type 2 Diabetes. JAMA Netw Open. 2022; 5(2):e2148317. PMC: 8845022. DOI: 10.1001/jamanetworkopen.2021.48317. View

19.

Yan J, Cohen R, Aminian A . Reoperative bariatric surgery for treatment of type 2 diabetes mellitus. Surg Obes Relat Dis. 2017; 13(8):1412-1421. DOI: 10.1016/j.soard.2017.04.019. View

20.

Koh Z, Chew C, Zhang J, Syn N, Kim G, So J . Metabolic outcomes after revisional bariatric surgery: a systematic review and meta-analysis. Surg Obes Relat Dis. 2020; 16(10):1442-1454. DOI: 10.1016/j.soard.2020.05.029. View